Skip to main content

Market Overview

Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers

  • Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study.
  • MYMD-1 is being evaluated for autoimmune and age-related diseases.
  • The new findings indicate the potential of MYMD-1 to limit the fibrotic biology associated with idiopathic pulmonary fibrosis. MYMD-1 demonstrated inhibition of transforming growth factor-beta, a driver for fibrosis, and tumor necrosis factor, associated with inflammation.
  • MyMD plans to move forward in testing combinations of MyMD-1 with approved fibrosis drugs.
  • In November last year, Akers Biosciences and MyMD announced a merger agreement.
  • Price Action: AKER is down 9.8% at $3.12 in market trading hours on the last check Tuesday.

Related Articles (AKER)

View Comments and Join the Discussion!

Posted-In: autoimmune diseasesBiotech M&A News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at